tiprankstipranks
Trending News
More News >

Recordati Reports Strong Q1 2025 Results with Double-Digit Revenue Growth

Story Highlights
Recordati Reports Strong Q1 2025 Results with Double-Digit Revenue Growth

Confident Investing Starts Here:

Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) just unveiled an announcement.

Recordati has reported strong financial performance in the first quarter of 2025, with consolidated net revenues increasing by 11.9% to €680.0 million. The company’s growth is driven by robust performance in its Specialty & Primary Care and Rare Diseases segments, with significant contributions from the extension of Isturisa’s indication and the approval of Signifor LAR in China. The company maintains its financial targets for 2025 and anticipates continued momentum through 2027, supported by strategic growth initiatives and disciplined cost management.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica S.p.A. operates in the pharmaceutical industry, focusing on Specialty & Primary Care and Rare Diseases. The company is known for its development and distribution of pharmaceuticals, with a market focus on both common and rare conditions.

Average Trading Volume: 471,350

Technical Sentiment Signal: Buy

Current Market Cap: €10.98B

See more insights into REC stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App